CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 42 enrolled
Drug / intervention
PM01183 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02448537
NCT02448537Phase 2Completed
CompareCT.gov

A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas

Massachusetts General Hospital·interventional·Posted May 19, 2015·Updated Mar 3, 2021

In Brief

A Phase 2 clinical trial evaluating PM01183, Doxorubicin, and 1 other intervention for Metastatic Sarcoma. Completed, enrolled 42 participants across 2 sites.

Detailed Summary

This research study is investigating a drug called PM01183 alone and in combination with chemotherapy drugs called gemcitabine or doxorubicin as a possible treatment for metastatic or unresectable Sarcoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Sarcoma
CountriesUnited States
CollaboratorsDana-Farber Cancer Institute, PharmaMar

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 19, 2015
Enrollment StartAug 1, 2015
Primary CompletionFeb 1, 2017
Study CompletionApr 1, 2019
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 11.1 years ago

Interventions

PM01183drug

Doxorubicindrug

Gemcitabinedrug